{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:00:08Z","timestamp":1783983608077,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2013,10,29]],"date-time":"2013-10-29T00:00:00Z","timestamp":1383004800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s11102-013-0530-0","type":"journal-article","created":{"date-parts":[[2013,10,28]],"date-time":"2013-10-28T09:17:47Z","timestamp":1382951867000},"page":"4-10","source":"Crossref","is-referenced-by-count":7,"title":["The role of primary pharmacological therapy in acromegaly"],"prefix":"10.1007","volume":"17","author":[{"given":"Ana Laura Espinosa","family":"de los Monteros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen A.","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo Adolfo Reza","family":"Albarr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alin","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,29]]},"reference":[{"issue":"11","key":"530_CR1","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","volume":"119","author":"S Melmed","year":"2009","unstructured":"Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189\u20133202","journal-title":"J Clin Invest"},{"issue":"5","key":"530_CR2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrendo.2011.42","volume":"7","author":"M Sherlock","year":"2011","unstructured":"Sherlock M, Woods C, Sheppard MC (2011) Medical therapy in acromegaly. Nat Rev Endocrinol 7(5):291\u2013300","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"530_CR3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11102-009-0206-y","volume":"13","author":"A Barkan","year":"2010","unstructured":"Barkan A, Bronstein MD, Bruno OD, Cob A, Espinosa-de-los-Monteros AL, Gadelha MR, Garavito G, Guitelman M, Mangupli R, Mercado M, Portocarrero L, Sheppard M (2010) Management of acromegaly in Latin America: expert panel recommendations. Pituitary 13(2):168\u2013175","journal-title":"Pituitary"},{"key":"530_CR4","doi-asserted-by":"crossref","unstructured":"Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK; American Association of Clinical Endocrinologists (2011) American Association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly\u20132011 update. Endocr Pract 17(Suppl 4):1\u201344","DOI":"10.4158\/EP.17.4.636"},{"key":"530_CR5","doi-asserted-by":"crossref","unstructured":"Vallette S, Ezzat S, Chik C, Ur E, Imran SA, Uum S, Rivera J, Caspar-Bell G, Serri O (2012) Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin Endocrinol (Oxf) 2012 Nov 28. doi: 10.1111\/cen.12112 . [Epub ahead of print]","DOI":"10.1111\/cen.12112"},{"issue":"5","key":"530_CR6","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","volume":"94","author":"S Melmed","year":"2009","unstructured":"Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A, Acromegaly Consensus Group (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509\u20131517","journal-title":"J Clin Endocrinol Metab"},{"key":"530_CR7","doi-asserted-by":"crossref","first-page":"306094","DOI":"10.1155\/2012\/306094","volume":"2012","author":"G Guinto","year":"2012","unstructured":"Guinto G, Abdo M, Zepeda E, Ar\u00e9chiga N, Mercado M (2012) Acromegaly: role of surgery in the therapeutic armamentarium. Int J Endocrinol 2012:306094","journal-title":"Int J Endocrinol"},{"issue":"9","key":"530_CR8","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1210\/jc.2010-0670","volume":"95","author":"L Katznelson","year":"2010","unstructured":"Katznelson L (2010) Approach to the patient with persistent acromegaly after pituitary surgery. J Clin Endocrinol Metab 95(9):4114\u20134123","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"530_CR9","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2165\/11318510-000000000-00000","volume":"69","author":"RA Feelders","year":"2009","unstructured":"Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely AJ (2009) Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 69(16):2207\u20132226","journal-title":"Drugs"},{"issue":"2","key":"530_CR10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11102-010-0269-9","volume":"14","author":"A Giustina","year":"2011","unstructured":"Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, Melmed S (2011) Current management practices for acromegaly: an international survey. Pituitary 14(2):125\u2013133","journal-title":"Pituitary"},{"issue":"8","key":"530_CR11","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1210\/jc.2005-0260","volume":"90","author":"PU Freda","year":"2005","unstructured":"Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90(8):4465\u20134473","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"530_CR12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","volume":"66","author":"M Mercado","year":"2007","unstructured":"Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J, SMS995B2401 Study Group (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66(6):859\u2013868","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"530_CR13","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1210\/jc.2005-2347","volume":"91","author":"R Cozzi","year":"2006","unstructured":"Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9\u00a0years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91(4):1397\u20131403","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"530_CR14","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2009-0941","volume":"94","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for 5\u00a0years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 94(10):3746\u20133756","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"530_CR15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","volume":"32","author":"A Colao","year":"2011","unstructured":"Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32(2):247\u2013271","journal-title":"Endocr Rev"},{"issue":"5","key":"530_CR16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","volume":"25","author":"MR Gadelha","year":"2013","unstructured":"Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 25(5):238\u2013248","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"530_CR17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2265.2008.03208.x","volume":"69","author":"P Chanson","year":"2008","unstructured":"Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B, Group Lanreotide Acromegaly Study (2008) Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48\u00a0weeks in patients with acromegaly. Clin Endocrinol (Oxf) 69(2):299\u2013305","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"530_CR18","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1210\/jc.2008-0299","volume":"93","author":"A Colao","year":"2008","unstructured":"Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G (2008) Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 93(7):2639\u20132646","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"530_CR19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11102-011-0318-z","volume":"15","author":"A Colao","year":"2012","unstructured":"Colao A (2012) Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 15(1):50\u201358","journal-title":"Pituitary"},{"issue":"1","key":"530_CR20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.0300-0664.2001.01438.x","volume":"56","author":"G Amato","year":"2002","unstructured":"Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C (2002) Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56(1):65\u201371","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"530_CR21","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1210\/jc.2004-2466","volume":"90","author":"S Melmed","year":"2005","unstructured":"Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90(7):4405\u20134410","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"530_CR22","doi-asserted-by":"crossref","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","volume":"7","author":"A Giustina","year":"2012","unstructured":"Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S (2012) Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7(5):e36411","journal-title":"PLoS ONE"},{"issue":"2","key":"530_CR23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11102-010-0282-z","volume":"14","author":"M Fleseriu","year":"2011","unstructured":"Fleseriu M (2011) Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 14(2):184\u2013193","journal-title":"Pituitary"},{"issue":"10","key":"530_CR24","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s12325-011-0062-9","volume":"28","author":"WH Ludlam","year":"2011","unstructured":"Ludlam WH, Anthony L (2011) Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther 28(10):825\u2013841","journal-title":"Adv Ther"},{"issue":"4","key":"530_CR25","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1210\/jc.2008-1420","volume":"94","author":"M Sherlock","year":"2009","unstructured":"Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM (2009) Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J Clin Endocrinol Metab 94(4):1255\u20131263","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"530_CR26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","volume":"96","author":"L Sandret","year":"2011","unstructured":"Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96(5):1327\u20131335","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"530_CR27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/eje.1.02312","volume":"156","author":"I Schreiber","year":"2007","unstructured":"Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ, German PegvisomantInvestigators (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156(1):75\u201382","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"530_CR28","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1530\/EJE-09-0322","volume":"161","author":"PJ Trainer","year":"2009","unstructured":"Trainer PJ (2009) ACROSTUDY: the first 5\u00a0years. Eur J Endocrinol 161(Suppl 1):S19\u2013S24","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"530_CR29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","volume":"154","author":"A Colao","year":"2006","unstructured":"Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154(3):467\u2013477","journal-title":"Eur J Endocrinol"},{"issue":"9471","key":"530_CR30","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(05)63011-5","volume":"365","author":"J Feenstra","year":"2005","unstructured":"Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365(9471):1644\u20131646","journal-title":"Lancet"},{"issue":"12","key":"530_CR31","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1210\/jc.2007-1234","volume":"92","author":"SJ Neggers","year":"2007","unstructured":"Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92(12):4598\u20134601","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"530_CR32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-10-0867","volume":"164","author":"AJ Lely van der","year":"2011","unstructured":"van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, Neggers S, Birman P (2011) Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 164(3):325\u2013333","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"530_CR33","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jcem-67-5-1040","volume":"67","author":"AL Barkan","year":"1988","unstructured":"Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67(5):1040\u20131048","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"530_CR34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3171\/jns.1994.81.1.0010","volume":"81","author":"T Lucas-Morante","year":"1994","unstructured":"Lucas-Morante T, Garc\u00eda-Ur\u00eda J, Estrada J, Saucedo G, Cabello A, Alca\u00f1iz J, Barcel\u00f3 B (1994) Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 81(1):10\u201314","journal-title":"J Neurosurg"},{"issue":"Suppl 1","key":"530_CR35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0026-0495(96)90088-8","volume":"45","author":"A Stevenaert","year":"1996","unstructured":"Stevenaert A, Beckers A (1996) Presurgical octreotide: treatment in acromegaly. Metabolism 45(Suppl 1):72\u201374","journal-title":"Metabolism"},{"issue":"10","key":"530_CR36","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1210\/jcem.82.10.4283","volume":"82","author":"A Colao","year":"1997","unstructured":"Colao A, Ferone D, Cappabianca P, Del De Basso Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cal\u00ec A, de Divitiis E, Lombardi G (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82(10):3308\u20133314","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"530_CR37","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1210\/jc.2008-0315","volume":"93","author":"SM Carlsen","year":"2008","unstructured":"Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J, Preoperative Octreotide Treatment of Acromegaly Study Group (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cures short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93(8):2984\u20132990","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"530_CR38","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1530\/EJE-09-0908","volume":"162","author":"ZG Mao","year":"2010","unstructured":"Mao ZG, Zhu YH, Tang HL, Wang DY, Zhou J, He DS, Lan H, Luo BN, Wang HJ (2010) Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 162(4):661\u2013666","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"530_CR39","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1210\/jcem.84.10.6027","volume":"84","author":"NR Biermasz","year":"1999","unstructured":"Biermasz NR, van Dulken H, Roelfsema F (1999) Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 84(10):3551\u20133555","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"530_CR40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s007010050316","volume":"141","author":"RA Kristof","year":"1999","unstructured":"Kristof RA, Stoffel-Wagner B, Klingm\u00fcller D, Schramm J (1999) Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 141(4):399\u2013405","journal-title":"A randomized study. Acta Neurochir (Wien)"},{"issue":"2","key":"530_CR41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/eje.0.1450137","volume":"145","author":"T Abe","year":"2001","unstructured":"Abe T, L\u00fcdecke DK (2001) Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145(2):137\u2013145","journal-title":"Eur J Endocrinol"},{"key":"530_CR42","doi-asserted-by":"crossref","unstructured":"Pl\u00f6ckinger U, Quabbe HJ (2005) Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case\u2013control study Acta Neurochir (Wien) 147(5):485\u2013493","DOI":"10.1007\/s00701-005-0511-9"},{"issue":"6","key":"530_CR43","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/BF03345797","volume":"35","author":"D Ferone","year":"2012","unstructured":"Ferone D, Gatto F, Minuto F (2012) Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for. J Endocrinol Invest 35(6):613\u2013615","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"530_CR44","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/BF03345798","volume":"35","author":"M Losa","year":"2012","unstructured":"Losa M, Crippa VG (2012) Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case against. J Endocrinol Invest 35(6):616\u2013618","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"530_CR45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1530\/eje.1.01824","volume":"152","author":"P Petrossians","year":"2005","unstructured":"Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A (2005) Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 152(1):61\u201366","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"530_CR46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1210\/jc.2005-1208","volume":"91","author":"A Colao","year":"2006","unstructured":"Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R (2006) Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91(1):85\u201392","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"530_CR47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2265.2007.02885.x","volume":"67","author":"RS Jallad","year":"2007","unstructured":"Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD (2007) Does partial surgical tumor removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 67(2):310\u2013315","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"530_CR48","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1365-2265.2007.03139.x","volume":"68","author":"N Karavitaki","year":"2008","unstructured":"Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ, Wass JA (2008) Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 68(6):970\u2013975","journal-title":"Clin Endocrinol (Oxf)"},{"key":"530_CR49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000318508","volume":"38","author":"MD Bronstein","year":"2010","unstructured":"Bronstein MD (2010) Optimizing acromegaly treatment. Front Horm Res 38:174\u2013183","journal-title":"Front Horm Res"},{"issue":"2","key":"530_CR50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1590\/S0004-27302011000200001","volume":"55","author":"L Vieira Neto","year":"2011","unstructured":"Vieira Neto L, Abucham J, Araujo LA, Boguszewski CL, Bronstein MD, Czepielewski M, Jallad RS, Musolino NR, Naves LA, Ribeiro-Oliveira A Jr, Vilar L, Faria Mdos S, Gadelha MR (2011) Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol 55(2):91\u2013105","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"5","key":"530_CR51","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1530\/EJE-07-0366","volume":"157","author":"P Abrams","year":"2007","unstructured":"Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J (2007) Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol 157(5):571\u2013577","journal-title":"Eur J Endocrinol"},{"key":"530_CR52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.arcmed.2011.01.004","volume":"42","author":"B Gonzalez","year":"2011","unstructured":"Gonzalez B, Vargas G, de los Espinosa Monteros AL, Sosa E, Mercado M (2011) Efficacy and safety of radiotherapy in acromegaly. Arch Med Res 42:48\u201352","journal-title":"Arch Med Res"},{"key":"530_CR53","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1210\/jc.2002-021663","volume":"88","author":"R Attanasio","year":"2003","unstructured":"Attanasio R, Epaminonda P, Motti E (2003) Gamma-knife radiosurgery in acromegaly: a 4\u00a0year follow-up study. J Clin Endocrinol Metab 88:3105\u20133112","journal-title":"J Clin Endocrinol Metab"},{"key":"530_CR54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1530\/EJE-11-0738","volume":"166","author":"C Ramirez","year":"2012","unstructured":"Ramirez C, Vargas G, Gonzalez B, Grossman A, Rabago J, Sosa E, De los Espinosa Monteros AL, Mercado M (2012) Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? Eur J Endocrinol 166:21\u201326","journal-title":"Eur J Endocrinol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-013-0530-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-013-0530-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-013-0530-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T18:43:07Z","timestamp":1646937787000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-013-0530-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,29]]},"references-count":54,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["530"],"URL":"https:\/\/doi.org\/10.1007\/s11102-013-0530-0","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,29]]}}}